Summary Tildrakizumab is a fairly new type of medicine called a biologic, used for the treatment of moderate‐to‐severe psoriasis. The drug prevents the action of a specific molecule in the body involved in inflammation, known as cytokine interleukin (IL)‐23p19. Previous studies have shown it to be superior to a placebo (an inactive substance, like a “sugar pill”) and to an older biologic drug, the TNF inhibitor etanercept.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with A.B.
Contact A.B., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack